Esanex, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.esanexpharma.com
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02973399
- Locations
- 🇺🇸
Wexner Medical Center, Ohio State University, Columbus, Ohio, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Esanex Inc.
- Registration Number
- NCT02914327
- Locations
- 🇺🇸
Wexner Medical Center, Ohio State University, Columbus, Ohio, United States
Study of SNX-5422 in TP53 Null Cancers
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02612285
- Locations
- 🇺🇸
Wexner Medical Center, Ohio State University, Columbus, Ohio, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02063958
- Locations
- 🇺🇸
Stanford Medicine, Stanford, California, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01892046
- Locations
- 🇺🇸
Georgia Regents University Cancer Center, Augusta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Georgetown University Medical Center, Washington, D.C., District of Columbia, United States
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01851096
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01848756
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01635712
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸Georgia Regents University Cancer Center, Augusta, Georgia, United States
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01611623
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
- Conditions
- Lymphoid Malignancy (Lymphoma and CLL)LeukemiaLymphomaSolid Tumor Malignancy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2012-05-17
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00647764
- Locations
- 🇺🇸
Pfizer Investigational Site, Bethesda, Maryland, United States